Dr Patricia Daniella Zuccaro, MD | |
5841 S Maryland Ave, Chicago, IL 60637-1443 | |
(773) 702-1000 | |
Not Available |
Full Name | Dr Patricia Daniella Zuccaro |
---|---|
Gender | Female |
Speciality | Internal Medicine - Infectious Disease |
Location | 5841 S Maryland Ave, Chicago, Illinois |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427580588 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | 036161050 (Illinois) | Primary |
Entity Name | University Of Chicago |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1821048786 PECOS PAC ID: 7719899426 Enrollment ID: O20031103000094 |
News Archive
Medical device pioneer Stentys announced today the results on 20 patients participating in the Company's ‘APPOSITION I' clinical study—the world's first to treat patients with acute myocardial infarction (AMI) via a self-expanding stent. These data were disclosed today by the study's principal investigator, Christian Spaulding, M.D., Ph.D., to an audience of cardiologists during a Stentys-hosted satellite meeting at the Transcatheter Cardiovascular Therapeutics ("TCT") 2009 annual scientific meeting.
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
While national immunization rates remain high, vaccine refusals are troubling. In some parts of the country, pockets of unimmunized children have left communities vulnerable to vaccine-preventable diseases, leading to outbreaks.
Microsulis reports that the groundbreaking Accu2i pMTA system for destroying unwanted tissue and used in the treatment of liver and other cancers now carries an impressive range of electrical safety standards. The Accu2i is CE-marked and carries FDA 510(k) clearance and so is cleared for electrical safety and performance with the internationally recognised standard IEC 60601-1 for electrical safety.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
› Verified 7 days ago
Entity Name | The University Of Chicago Medical Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1033218128 PECOS PAC ID: 7618880766 Enrollment ID: O20031106000203 |
News Archive
Medical device pioneer Stentys announced today the results on 20 patients participating in the Company's ‘APPOSITION I' clinical study—the world's first to treat patients with acute myocardial infarction (AMI) via a self-expanding stent. These data were disclosed today by the study's principal investigator, Christian Spaulding, M.D., Ph.D., to an audience of cardiologists during a Stentys-hosted satellite meeting at the Transcatheter Cardiovascular Therapeutics ("TCT") 2009 annual scientific meeting.
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
While national immunization rates remain high, vaccine refusals are troubling. In some parts of the country, pockets of unimmunized children have left communities vulnerable to vaccine-preventable diseases, leading to outbreaks.
Microsulis reports that the groundbreaking Accu2i pMTA system for destroying unwanted tissue and used in the treatment of liver and other cancers now carries an impressive range of electrical safety standards. The Accu2i is CE-marked and carries FDA 510(k) clearance and so is cleared for electrical safety and performance with the internationally recognised standard IEC 60601-1 for electrical safety.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Patricia Daniella Zuccaro, MD 150 Harvester Dr Ste 300, Burr Ridge, IL 60527-5965 Ph: (773) 702-1061 | Dr Patricia Daniella Zuccaro, MD 5841 S Maryland Ave, Chicago, IL 60637-1443 Ph: (773) 702-1000 |
News Archive
Medical device pioneer Stentys announced today the results on 20 patients participating in the Company's ‘APPOSITION I' clinical study—the world's first to treat patients with acute myocardial infarction (AMI) via a self-expanding stent. These data were disclosed today by the study's principal investigator, Christian Spaulding, M.D., Ph.D., to an audience of cardiologists during a Stentys-hosted satellite meeting at the Transcatheter Cardiovascular Therapeutics ("TCT") 2009 annual scientific meeting.
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
While national immunization rates remain high, vaccine refusals are troubling. In some parts of the country, pockets of unimmunized children have left communities vulnerable to vaccine-preventable diseases, leading to outbreaks.
Microsulis reports that the groundbreaking Accu2i pMTA system for destroying unwanted tissue and used in the treatment of liver and other cancers now carries an impressive range of electrical safety standards. The Accu2i is CE-marked and carries FDA 510(k) clearance and so is cleared for electrical safety and performance with the internationally recognised standard IEC 60601-1 for electrical safety.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
› Verified 7 days ago
Dr. Sorin C Danciu, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3134 N Clark St, Chicago, IL 60657 Phone: 773-880-9722 | |
Anoopa A. Koshy, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 2200, Chicago, IL 60611 Phone: 312-926-6000 | |
William Edmond Gerardi, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 3730 N Lake Shore Dr, Apartment 2a, Chicago, IL 60613 Phone: 773-244-3060 | |
Suparna Dutta, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 W Van Buren St, Suite 500, Chicago, IL 60612 Phone: 312-942-4200 Fax: 312-942-3568 | |
Alexandra Dumitrescu, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 888-824-0200 | |
Dr. Mitesh Mahesh Kabadi, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St Ste 1159, Chicago, IL 60612 Phone: 312-942-5020 | |
Dr. Marta Batus, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St, Suite 809, Chicago, IL 60612 Phone: 312-563-2487 Fax: 312-942-3192 |